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Objective: Left ventricular assist device implantation is associated with an increased
risk of development of circulating anti-HLA class I and II antibodies (sensitization).
We investigated the impact of sensitization on posttransplantation outcomes in 105
consecutive left ventricular assist device recipients.
Methods: Five hundred twenty-one consecutive adult cardiac allograft recipients
between 1992 and 1999 were retrospectively studied. Of these, 105 were supported
with a left ventricular assist device. Pretransplantation and posttransplantation
antibody production, time to transplantation after listing, rejection, freedom from
transplant coronary artery disease, and survival were evaluated by Kaplan-Meier
analysis. Among sensitized left ventricular assist device recipients, 26 were treated
with a pretransplantation immunomodulatory regimen consisting of intravenous
immunoglobulin and cyclophosphamide.
Results: There were no significant differences between left ventricular assist device
recipients and nonbridged recipients with respect to pretransplantation demographic
characteristics and ABO and HLA matching. Among left ventricular assist device
recipients, 66% (69/105) were sensitized before transplantation; in contrast, only 6%
(24/399) of nonbridged recipients were sensitized (P  .001). Sensitized untreated
left ventricular assist device recipients had both a prolongation of waiting time to
transplantation and an increased risk of acute rejection. Pretransplantation immu-
nomodulatory therapy reduced both the increased waiting time and the increased
risk of acute rejection. However, sensitization or the use of immunomodulatory
therapy in left ventricular assist device–bridged recipients did not influence post-
transplantation survival relative to nonbridged recipients.
Conclusions: Left ventricular assist device recipients have survival outcomes similar
to those of nonbridged recipients after cardiac transplantation, despite their signif-
icantly higher immunologic risk. The reduced rate of transplantation and the
increased incidence of rejection observed in sensitized left ventricular assist device
recipients are prevented by immunomodulatory therapy. Sensitization will remain
an important issue with increased use of left ventricular assist devices, and improved
understanding of this is essential to achieve better outcomes in the management of
patients with end-stage heart failure.
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The development of circulating antibodies,termed sensitization, may occur as a result ofprevious blood transfusions, previous preg-nancies, a previous allograft, and, more re-cently, the presence of a left ventricular as-sist device (LVAD).1,2 It is well known that
human renal allografts in sensitized recipients may undergo
fulminant rejection within minutes or hours of revascular-
ization.3 This pattern of hyperacute rejection almost never
occurs today because of current immunologic monitoring
protocols. In a 1969 landmark study, Patel and Terasaki4
established that a prospective negative crossmatch between
donor lymphocytes and recipient serum is the single best
predictor of short-term allograft survival. The presence of
preformed lymphocytotoxic antibodies reactive against do-
nor lymphocytes in recipient serum (a positive donor-spe-
cific crossmatch) is considered a contraindication to solid
organ transplantation because of the high incidence of hu-
moral allograft rejection, increased risk of early graft fail-
ure, and poorer patient survival.5-7 Current standards in
kidney transplantation mandate a crossmatch between do-
nor-recipient pairs before transplantation. However, con-
straints of prolonged ischemic time do not allow cross-
matching to be a routine test in cardiac transplantation. A
much less precise surrogate to ensure immunologic compat-
ibility has been the use of panel reactive antibody (PRA)
testing.
The proportion of highly sensitized patients on cardiac
transplant waiting lists has been progressively expanding in
recent years as a result of widespread use of left ventricular
assist devices (LVAD) and increasing numbers of patients
undergoing retransplantation.8,9 LVAD recipients have
prominent B-cell activation, as evidenced by heightened
production of anti-HLA class I and class II immunoglobulin
G (IgG) antibodies.10 Although use of leukocyte-filtered
platelets can partially reduce anti-HLA class I antibody
production, B-cell hyperreactivity associated with
LVAD implantation results from a multifactorial dys-
regulatory process involving heightened T-cell apoptosis,
selective loss of TH1 type T cells, and unopposed produc-
tion of TH2 cytokines.11 As a consequence of circulating
anti-HLA class I and class II antibodies, LVAD recipients
are subject to repeated positive crossmatches, increased
waiting time to cardiac transplantation, and heightened risk
of cellular rejection after transplantation. In this large sin-
gle-center study we investigated the impact of sensitization
in LVAD recipients on posttransplantation outcomes rela-
tive to nonbridged cardiac allograft recipients and evaluated
the influence of immunologically focused interventions to
prevent the adverse immunologic and clinical effects of
sensitization on LVAD recipients undergoing cardiac trans-
plantation.
Methods
Patients
Between January 1992 and November 1999, a total of 521 con-
secutive primary transplants were performed on adult (age 18
years) recipients at the Columbia Presbyterian Medical Center.
The patients were predominantly male (78.1%) and white (81.3%),
with a mean age of 50.8  12.7 years. The major pretransplanta-
tion diagnosis was ischemic cardiomyopathy (62%), followed by
idiopathic cardiomyopathy (26%), congenital heart disease (5%),
and others (7%). One hundred five patients (20%) were supported
with LVADs before transplantation.
Clinical Data
The following pretransplantation variables were analyzed: recipi-
ent age, recipient sex, recipient ethnicity, pretransplantation diag-
nosis, pretransplantation cytomegalovirus infection, donor age,
donor sex, donor race, ischemic time, and HLA-A, HLA-B, and
HLA-DR mismatches. The pretransplantation development of IgG
anti-HLA class I and II antibodies and waiting time to transplan-
tation were evaluated as part of the pretransplantation analysis. In
the posttransplantation period, data on acute rejection, transplant-
related coronary artery disease (TCAD), and survival were evalu-
ated and compared between the groups.
Operative Techniques
Hearts were harvested from beating-heart, brain-dead donors.
Graft procurement and preservation used cold cardioplegic arrest
with University of Wisconsin solution and topical hypothermia.
From 1992 through 1996, orthotopic cardiac transplantation was
performed with the biatrial technique described by Lower and
Shumway.12 Since 1996 we have performed almost all transplants
with the bicaval anastomosis technique.
Immunosuppressive Regimen
All patients received triple immunosuppression consisting of cy-
closporine, steroids, and azathioprine. Azathioprine was given at
an initial preoperative dose of 4 mg/(kg  d), followed by a daily
intravenous dose of 2 mg/kg until the patient could tolerate oral
medication. Since 1996 azathioprine has been replaced by myco-
phenolate mofetil, starting at a dose of 1000 mg twice daily.
Cyclosporine was given at the initial dose of 1 to 2 mg/(kg  d),
which was adjusted to maintain trough whole blood levels between
300 and 350 ng/dL. Between 3 and 6 months after transplantation
cyclosporine dosage was adjusted to maintain blood cyclosporine
levels between 150 and 250 ng/dL, and after 6 months the levels
were kept between 100 and 150 ng/dL. Methylprednisolone (500
mg) was administered intravenously during the operation and in
the postoperative period at a dose of 125 mg every 8 hours over 24
hours. Prednisone was given in tapering doses from 1 mg/(kg d)
immediately after the operation to 0.1 mg/(kg  d) by the fourth
month. Rejection episodes were treated with oral or intravenous
pulses of steroid at 100 mg/d for 3 days followed by a taper over
1 week to the baseline dose. Patients without response to steroid
therapy were treated with cytolytic therapy (OKT3 or ATGAM).
Early in our experience (1992-1996) we noted the development
of sensitization in LVAD-supported patients and the subsequent
deleterious effects of sensitization.13 On the basis of this experi-
ence, we devised and subsequently instituted a treatment regimen
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consisting of cyclophosphamide and intravenous immunoglobulin
(IVIg) for all sensitized patients from 1997 onward. Twenty-six
sensitized LVAD recipients with anti-HLA antibodies awaiting
cardiac transplantation received a treatment regimen consisting of
1 to 3 monthly courses of cyclophosphamide given intravenously
in a single infusion dose of 0.5 to 1.0 g/m2 together with pooled
human IVIg at 2 g/kg given in four divided daily doses. Mesna was
intravenously coadministered immediately before and after cyclo-
phosphamide infusion and at the same total dosage to prevent toxic
effects of breakdown metabolites on bladder mucosa.
Each sensitized patient received a monthly treatment course
consisting of cyclophosphamide and IVIg. Anti-HLA antibody
levels were measured at weekly intervals from the date of onset of
treatment. Multiple courses (3) were administered to patients
who did not have a significant drop in anti-HLA antibody levels
with the initial course. All 26 sensitized cardiac allograft recipients
were treated with triple immunosuppression that included monthly
posttransplantation pulses of intravenous cyclophosphamide at 0.5
to 1.0 g/m2 for 4 months instead of mycophenolate mofetil
(MMF). These patients subsequently received mycophenolate
mofetil for the remainder of the posttransplantation period.
Acute Rejection
The diagnosis of acute rejection was based on clinical symptoms
and confirmed by endomyocardial biopsy performed weekly for
the first 3 weeks, every second week for the next three biopsies,
every 3 weeks for the next three biopsies, monthly for the first
year, and every other month thereafter. The biopsy specimens were
graded according to International Society for Heart and Lung
Transplantation criteria.14 High-grade cellular allograft rejection
was defined pathologically as at least grade 3A or 3B.
Angiography and Diagnosis of TCAD
Patients underwent annual coronary angiography. The diagnosis of
TCAD was based on the following criteria: (1) discrete lesions
resulting in more than 50% obstruction of the proximal or mid
portions of major graft vessels or (2) diffuse, concentric narrowing
of the whole vessels, including their branches. If TCAD was
found, the frequency of angiography was increased to a biennial
regimen. Patients were not given routine vasodilators before cor-
onary injections. All angiograms were reviewed by a cardiologist
and compared with the previous year’s films to detect the presence
of luminal irregularities, discrete stenoses, loss of third-order
branches, or pruning of vessels. Explanted hearts and autopsy
specimens were examined for evidence of vessel occlusion and
irregularities, ischemic damage, and presence of acute cardiac
rejection.
HLA Typing
Serologic typing of HLA-A and HLA-B loci was performed by
standard microcytotoxicity techniques. HLA-DR typing was per-
formed by serologic analysis.
Detection of Anti-HLA Antibodies
Serum samples were obtained from all patients on the day of
transplantation and screened for the presence of lymphocytotoxic
antibodies against separated T lymphocytes and B lymphocytes
obtained from a panel of 70 individuals representative of all HLA
class I and class II antigens found in the North American popula-
tion. A negative prospective donor-specific lymphocytic cross-
match was required before transplantation when the anti-HLA
antibody reactivity was greater than 20%.
Pretransplantation serum samples were obtained from all pa-
tients at risk for sensitization on the day of initial United Network
for Organ Sharing listing for transplantation and then every 2
weeks until transplantation. In sensitized patients undergoing treat-
ment, anti-HLA antibody levels were measured at weekly intervals
from the date of treatment until transplantation. All sensitized
patients, irrespective of whether immunomodulatory therapy was
used, underwent a prospective donor specific lymphocytotoxic
crossmatch. Posttransplantation serum samples were obtained
from all patients with each biopsy.
Determination of Anti-HLA Antibody Specificity for
Major Histocompatibility Complex Class I or Class II
Antigens
Working definitions for IgG antibodies against HLA class I mol-
ecules or class II molecules were established in our laboratory with
serum samples from 28 heart transplant recipients with PRA
values greater than 10% as reference and with anti-HLA class I
and class II specificities defined by standard tail analysis as has
been described previously elsewhere.13
Statistical Analysis
Differences between groups were examined with the 2 or Fisher
exact test. Continuous variables were compared with a Student t
test if values were normally distributed; if not, a Wilcoxon rank
sum test was used. Survival estimates were based on the Kaplan-
Meier method, and curves were compared with a log-rank test.15
The cumulative rejection frequency used the method of Wei and
colleagues16 to produce tests and partial likelihood estimates for
repeated events. To obtain reliable and comparable relative odds of
transplantation for all groups, we arbitrarily chose a period of 2
months (the mean waiting time for status I patients is 2.4 months)
and compared probability of transplantation at that time in all
studied groups. However, we also studied the mean and median
waiting times for transplantation in all these groups for further
comparison. Values are reported as mean  SD. Data were ana-
lyzed with SAS System software version 6.14 (SAS Institute, Inc,
Cary, NC).
Results
Demographic Characteristics of LVAD Recipients
One hundred five of 521 heart transplant recipients (20%)
were supported before transplantation with LVADs. Demo-
graphic characteristics of all heart transplant recipients who
were bridged with LVADs before heart transplantation and
of nonbridged cardiac allograft recipients are shown in
Table 1. Sixty seven percent of LVAD recipients (70/105)
had a pretransplantation diagnosis of ischemic cardiomyop-
athy, in contrast to 57% of nonbridged cardiac allograft
recipients (236/416, P  .05). Other demographic data did
not differ statistically between the two groups. In addition,
ischemic time and recipient-donor HLA-A, HLA-B and
Surgery for Acquired Cardiovascular Disease John et al
580 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
A
CD
HLA-DR mismatching did not differ between the two
groups.
Waiting Times for LVAD Recipients
As seen in Table 1, most LVAD recipients (77%) were
initially listed as status I patients, in contrast to only 34% of
control recipients (P  .001). Of 97 LVAD recipients who
were enrolled on a United Network for Organ Sharing
waiting list between January 1992 and January 1999, 53%
(51/97) were listed as status I on the day of LVAD implan-
tation; the remaining 47% (46/97) were initially listed as
either status I (24/46, 52%) or status II (22/46, 48%) and
waited a mean duration of 3.9 7.5 months (range 0.1-41.8
months) for LVAD placement and subsequent conversion to
status I (Table 2). The mean time from LVAD placement to
transplantation was 3.13  1.7 months (Table 2).
High Prevalence of Pretransplantation Sensitization to
HLA Antigens Among LVAD Recipients
As shown in Table 3, 66% of patients receiving LVAD
support (69/105) had IgG antibodies directed against HLA
molecules develop, compared with only 6% of nonbridged
heart transplant recipients (24/399, P .001). The pretrans-
plantation production of IgG antibodies was directed against
both HLA class I and II molecules; 57% and 40% of LVAD
recipients had IgG anti-HLA class I and class II antibodies,
respectively, in contrast to only 4% and 4%, respectively, of
nonbridged transplant recipients (both P  .001).
Pretransplantation Sensitization With IgG Anti-HLA
Class I Antibodies and Prolonged Waiting Times to
Transplantation in LVAD Recipients
Pretransplantation sensitization with IgG anti-HLA antibod-
ies, in particular those directed against class I molecules,
prolonged waiting time from LVAD implantation to heart
transplantation. As illustrated in Table 4, the probability of
undergoing transplantation was increased 4-fold for LVAD
recipients who did not acquire IgG anti-HLA class I anti-
bodies relative to those who did (P .0001). Of 105 LVAD
recipients, only 17% patients with anti-HLA class I anti-
bodies received a heart transplant within 2 months from
LVAD implantation, versus 53% of control patients (P 
.0001. The development of anti-HLA IgG class II antibodies
also had an impact on waiting time to transplantation for
TABLE 1. Comparative statistics between LVAD-bridged and control recipients*
LVAD (n  105) Control (n  416) P value
Recipient sex (No. female) 17 (17%) 97 (23%) .12
Recipient ethnicity (No. nonwhite) 21 (20%) 76 (18%) .65
Recipient age (y, mean  SD) 50.6 12.6 51.4 11.8 .56
Recipient heart diagnosis (No.)
Ischemic heart disease 70 (67%) 236 (57%) .05
Idiopathic cardiomyopathy 24 (23%) 107 (26%) .58
Recipient cytomegalovirus testing (positive/tested) 52/72 (72%) 227/338 (67%) .40
Ischemic time (min, mean  SD) 173 54 170 46 .50
Complete mismatch (No.)
HLA-A locus 68 (69%) 223 (62%) .18
HLA-B locus 83 (85%) 283 (79%) .18
HLA-DR locus 69 (70%) 231 (65%) .32
Initial United Network for Organ Sharing listing (No.)
Status I 75 (77%) 104 (34%)
Status II 22 (23%) 198 (66%) .001
*Patients enrolled on United Network for Organ Sharing waiting list between January 1992 and January 1999.
TABLE 2. Comparison of waiting times between LVAD-
bridged and control recipients*
Waiting period
Waiting time (mo)
Mean  SD Median
From listing to LVAD implantation
Status I on day of LVAD implantation
(n  51)
0 0
Enrolled on waiting list before LVAD
placement (n  46)
3.90 7.5 1.3
From LVAD implantation to transplantation 3.13 1.7 3.1
From listing to transplantation (control)
Status I 1.46 1.7 0.61
Status II 4.30 2.0 5.64
*Patients enrolled on United Network for Organ Sharing waiting list be-
tween January 1992 and January 1999 only.
TABLE 3. Presence of IgG anti-HLA antibodies before or on
the day of transplantation in LVAD-bridged and control
recipients
LVAD Control P value
IgG anti-HLA (I or II) 69/105 (66%) 24/399 (6%) .001
IgG anti-HLA class I 60/105 (57%) 17/399 (4%) .001
IgG anti-HLA class II 43/105 (40%) 15/381 (4%) .001
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LVAD recipients. The probability of transplantation within
2 months of LVAD implantation was 2-fold lower for
LVAD recipients who did not acquire anti-HLA class II
antibodies (P  .05). For LVAD recipients who acquired
antibodies against either class I or II HLA molecules, the
probability of undergoing cardiac transplantation was 2.6-
fold higher than that of control nonsensitized LVAD recip-
ients (P  .005).
Treatment of presensitized LVAD recipients and short-
ened waiting times to transplantation. Table 5A and Table
5B compare the waiting times to transplantation of status I
(n  104) and status II (n  201) nonsensitized patients
with those of sensitized LVAD recipients (n  34), sensi-
tized untreated LVAD recipients (n  45), and sensitized
LVAD recipients who were treated with IVIg and cyclo-
phosphamide (n  26). Relative to status II recipients, the
probability of transplantation within 2 months from listing
was highest for status I patients (relative risk [RR] 6.160,
P .001), followed by nonsensitized LVAD recipients (RR
2.7, P  .001) and sensitized LVAD recipients who were
treated (RR 2.955, P  .001). Sensitized LVAD recipients
who did not receive any treatment had a likelihood of
undergoing transplantation similar to that of status II pa-
tients (RR 1.499, P  .18).
Influence of LVAD Bridging on Recipient Survivals
After Heart Transplantation
As seen in Table 6A, Table 6B, and Figure 1, A, 5-year
posttransplantation survival was comparable between
LVAD recipients (75%) and nonbridged transplant recipi-
ents (72%, P  .53). Because immunomodulatory regimens
for sensitized patients were introduced in 1997 and 1998, a
1-year analysis was thought to be most representative to
analyze the impact of immunomodulatory regimens for
pretransplantation LVAD sensitization on subsequent post-
transplantation survival, as illustrated in Table 6C. One-year
mortalities among nonsensitized, nonbridged status I and II
patients were 20% and 17%, respectively; these were not
statistically different from the mortalities in LVAD recipi-
ents who were not sensitized (18%), were sensitized and
untreated (16%), and were sensitized and treated (12%, P
.65). Figure 1, B, presents 5-year actuarial survivals among
these five groups (P not significant).
Prevention of Increased High-grade Acute Rejection
After Cardiac Transplantation in Sensitized LVAD
Recipients by IVIg and Cyclophosphamide Therapy
There was no correlation between pretransplantation LVAD
support and acute rejection after cardiac transplantation
relative to nonbridged cardiac allograft recipients (Figure 2,
A). As seen in Table 7A, the incidence of at least one
high-grade rejection episode within the first year after car-
diac transplantation was 39% among recipients who had
LVADs, versus 37% among nonbridged cardiac allograft
recipients (RR  0.93, P  0.71). A detailed analysis
comparing the five previously described groups of patients,
however, supports the hypothesis that transplant recipients
with pretransplantation LVAD support were not at an in-
creased risk for acute rejection after heart transplantation
unless they were sensitized with anti-HLA antibodies and
did not receive any immune intervention. As seen in Figure
2, B, and Table 7B, sensitized, untreated LVAD recipients
were at 2.7-fold greater risk for at least one high-grade acute
rejection within the first posttransplant year than were status
I or II patients. In fact, those LVAD recipients who were not
sensitized and those who were sensitized and treated had
significantly lower cumulative frequencies of rejection (0.3
and 0.28, respectively, P  .05).
Lack of Association in LVAD Recipients Between
Sensitization and Development of TCAD
There was no association between pretransplantation LVAD
support and development of TCAD. The incidence of
TCAD among LVAD-supported patients at the first annual
angiography (mean duration 18 months after transplanta-
tion) was 31%, versus 26% among control heart transplant
recipients (Figure 3, P  .49). Further, in LVAD recipients
pretransplantation sensitization and treatment did not affect
the development of TCAD, as shown in Table 8.
Safety Profiles of Pretransplantation and
Posttransplantation Immunosuppressive Therapy
Treatment with intravenously administered cyclophospha-
mide has proved to be extremely safe. Systemic fungal
infections occurred before transplantation in 22% of sensi-
tized LVAD recipients who did receive cyclophosphamide.
The incidence of cytomegalovirus disease (defined as clin-
ical disease together with virologic culture confirmation)
TABLE 4. Pretransplantation sensitization with IgG anti-
HLA antibodies, in particular directed against class I mol-
ecules, and prolonged waiting times to transplantation in
LVAD recipients
Transplanted
within 2 mo
RR
95%
Confidence
interval P valueNo. %
IgG anti-HLA class I
Sensitized 10/60 17 1
Control 24/45 53 4.219 2.014-8.841 .0001
IgG anti-HLA class II
Sensitized 9/43 21 1 1
Control 25/62 41 2.141 0.999-4.590 .050
IgG anti-HLA class I
or II
Sensitized 16/69 24 1
Control 18/36 50 2.635 1.342-5.173 .005
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after transplantation was 3 of 26 cyclophosphamide-treated
patients (12%). No other systemic viral, bacterial, or fungal
infections were seen in patients treated with cyclophospha-
mide. Cyclophosphamide therapy was frequently (80%)
accompanied by transient nausea and vomiting that re-
sponded to antiemetic therapy. Mesna was coadministered
with cyclophosphamide and may have contributed to the
absence of any cases of hemorrhagic cystitis. No malignan-
cies have developed after 53.5 patient-mo of follow-up
(range 6-38 months). IVIg therapy was associated with
immune complex disease in 4 of 26 monthly courses (15%),
as evidenced by fevers, arthralgias, and maculopapular
rashes. Reversible renal insufficiency (defined as 50%
increase in serum creatinine level) occurred in 4 cases.
Discussion
Historically, it was Medawar17 in 1946 who first described
the accelerated pace of skin graft rejection in rabbits chal-
lenged with donor blood relative to the process of acute
rejection in unsensitized animals. Later, Simonsen and as-
sociates18 showed that a second transplant from the original
canine donor and not from a third-party donor was rejected
faster than was the first organ. It was shown more than 30
TABLE 5A. Waiting times from LVAD implantation or enrollment onto a waiting list to heart transplantation*
Transplanted
within 2 mo
RR
95% Confidence
interval
Time to transplantation
(mo)
P valueNo. % Median Mean
Status I (n  104) 77 74 6.469 4.437-9.432 0.68 2.40 .0001
Status II (n  201) 43 21 1 — 5.63 8.69 —
LVAD (n  105) 47 45 1.545 0.985-2.423 2.51 3.01 .05
*Patients enrolled on United Network for Organ Sharing waiting list between January 1992 and January 1999 only.
TABLE 5B. Waiting times from LVAD implantation or enrollment onto a waiting list to heart transplantation*
Transplanted
within 2 mo
RR
95% Confidence
interval
Time to
transplantation (mo)
No. % Median Mean P value
Status 1 (n  104) 77 74 6.160 4.179-9.078 0.73 2.44 .0001
Status 2 (n  201) 43 22 1 — 5.69 8.74 —
LVAD not sensitized (n  34) 18 53 2.739 1.573-4.768 1.98 2.54 .0004
LVAD sensitized and treated (n  26) 14 54 2.955 1.610-5.424 1.70 2.48 .0005
LVAD sensitized (n  45) 15 33 1.499 0.830-2.708 2.83 3.66 .179
*Patients enrolled on United Network for Organ Sharing waiting list between January 1992 and January 1999 only.
TABLE 6A. Influence of LVAD bridging on survival after
heart transplantation
Survival
5 y after
transplantation
RR
95%
Confidence
interval P valueNo. %
Status I* (n  104) 71 68 1.469 0.941-2.293 .06
Status II* (n  201) 154 77 1 — —
LVAD (n  105) 79 75 1.056 0.576-1.588 .86
*Patients enrolled on United Network for Organ Sharing waiting list be-
tween January 1992 and January 1999 only.
TABLE 6B. Influence of LVAD bridging on survival after
heart transplantation
Survival
5 y after
transplantation
RR
95%
Confidence
interval P valueNo. %
LVAD (n  105) 79 75 0.862 0.543-1.367 .53
Control (n  416) 300 72 1 — —
TABLE 6C. Influence of LVAD bridging on survival after
heart transplantation
1-y
mortality RR
95%
Confidence
interval P value
Status 1* 20% 1.762 0.521-5.955 .36
Status 2* 17% 1 — —
LVAD not sensitized 18% 1.553 0.388-6.211 .53
LVAD sensitized 16% 1.314 0.340-5.083 .69
LVAD sensitized and
treated
12% 1.283 0.453-4.852 .51
*Patients enrolled on United Network for Organ Sharing waiting list be-
tween January 1992 and January 1999 only.
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Figure 1. Actuarial (Kaplan-Meier) survivals after heart transplantation. Symbols represent actual events, posi-
tioned along horizontal axis at time of event and by Kaplan-Meier method along vertical axis. A, Squares,
Nonbridged recipients; triangles, LVAD-bridged recipients. B, Filled squares, Sensitized and treated LVAD recip-
ients; triangles, unsensitized LVAD recipients; filled circles, sensitized untreated LVAD recipients; open circles,
status I recipients; open squares, unsensitized status II recipients.
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Figure 2. Actuarial (Kaplan-Meier) freedoms from high-grade acute rejection. Symbols represent actual events,
positioned along horizontal axis at time of event and by Kaplan-Meier method along vertical axis. A, Squares,
Nonbridged recipients; triangles, LVAD-bridged recipients. B, Filled squares, Unsensitized LVAD recipients;
triangles, sensitized and treated LVAD recipients; filled circles, sensitized untreated LVAD recipients; open circles,
status I recipients; open squares, status II recipients.
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years ago that human renal allografts in sensitized recipients
may undergo fulminant rejection within minutes or hours
after revascularization.3 Because of the historic concept that
rejection in sensitized individuals is driven primarily by the
humoral component of the host immune system, cellular
immune responses have received relatively less attention.
However, current concepts emphasize the interdependence
of the two pathways and recognize a key role for T cells,
primarily of the CD4 phenotype, and macrophages in the
initiation and control of B-cell differentiation and immuno-
globulin production through the elaboration of a number of
cytokine mediators.
As mentioned earlier, the classic risk factors for alloim-
munization in organ transplant recipients, including previ-
ous allografts, pregnancy, and blood transfusions, have been
extensively studied in renal allograft recipients. More re-
cently, sensitization in patients awaiting cardiac transplan-
tation has been of significant importance and has been
evaluated in detail. Our current experience shows that 66%
of patients receiving LVAD support acquired IgG antibod-
ies directed against HLA molecules, versus only 6% of
nonbridged heart transplant recipients. In an earlier analysis
of 40 patients receiving LVAD support while awaiting
cardiac transplantation at our institution, Moazami and col-
leagues19 observed that 80% of patients had development of
antibodies against major histocompatibility complex class I
or II antigen. Several risk factors, including previous preg-
nancy, transfusions, age, sex, concurrent risk factors, and
perioperative blood product use, were studied in an attempt
to predict risk factors for the development of these antibod-
ies. According to multivariate analysis, only platelet trans-
fusions were predictive of development of anti-HLA IgG
antibodies, with patients receiving more than 6 units of
platelets being at higher risk. However, the significance of
the importance of blood products in sensitization in patients
with heart failure receiving LVAD support while awaiting
cardiac transplantation is controversial. Stringham and col-
leagues20 used a strict protocol to avoid transfusion of
cellular blood products to LVAD recipients and concluded
that this did not universally protect these patients against
HLA allosensitization. They suggested that the use of fresh-
frozen plasma (which could contain small amounts of sol-
uble HLA antigens) and that previous cardiac surgery could
themselves influence sensitization. Massad and coworkers2
showed that there was no significant difference in the fre-
quency of HLA sensitization between LVAD recipients
tested before LVAD support and nonbridged patients tested
before cardiac transplantation; however, sensitization was
present in 66% of all patients tested after LVAD placement.
Further, a significant increase in mean PRA level occurred
during LVAD support. The influence of infections on sen-
sitization in patients receiving mechanical circulatory sup-
port is also controversial.21,22
It is also possible that the immunologic alterations in
recipients with LVADs may be directly related to interac-
tions between the LVAD surface and the host immune
system itself. We have shown that TCI LVAD implantation
(Thermo Cardiosystems, Inc, Woburn, Mass) is accompa-
nied by colonization of the LVAD surface with heteroge-
neous cellular populations composed primarily of mono-
cytes or macrophages and T cells.10 Detailed examination of
the T-cell populations on the LVAD surface demonstrated
heightened in vivo T-cell activation of both TH1 and TH2
type cells, as determined by markers of cellular activation
TABLE 7A. Influence of LVAD bridging on acute rejection after heart transplantation*
Rejection within 12 mo Frequency of
rejection at
12 mo P valueNo. % RR
95% Confidence
interval P value
LVAD (n  105) 40/103 39 1 — — 0.45 —
Control (n  416) 142/383 37 0.933 0.641-1.356 .71 0.53 .31
*Patients enrolled on United Network for Organ Sharing waiting list between January 1992 and January 1999 only.
TABLE 7B. Influence of LVAD bridging on acute rejection after heart transplantation*
Rejection within 12 mo Frequency of
rejection at
12 mo P valueNo. % RR
95% Confidence
interval P value
Status 1 not sensitized (n  89) 34 39 1.949 0.762-4.983 .16 0.54 .45
Status 2 not sensitized (n  175) 70 40 2.002 0.808-4.960 .14 0.62 —
LVAD not sensitized (n  33) 9 27 1.261 0.413-3.856 .68 0.3 .05
LVAD sensitized and treated (n  26) 6 22 1 — — 0.28 .03
LVAD sensitized (n  44) 25 48 2.732 1.030-7.247 .04 0.63 .93
*Patients enrolled on United Network for Organ Sharing waiting list between January 1992 and January 1999 only.
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and cytokine messenger RNA gene expression. As a result
of this heightened state of activation after exposure to the
LVAD surface, circulating T cells in LVAD recipients
demonstrated excessive T-cell apoptosis through CD95-
CD95L interactions, with a concomitant increase in produc-
tion of TH2 cytokines, particularly interleukin 10. Because
augmented levels of CD95-dependent T-cell apoptosis23,24
and a predominant TH2 type cytokine profile25,26 are fea-
tures also common to patients with systemic lupus erythem-
atosus, LVAD implantation may serve as an iatrogenic
model for diseases of B-cell hyperreactivity and autoanti-
body production.
The clinical implications of sensitization in LVAD re-
cipients awaiting cardiac transplantation are significantly
adverse in nature. The presence of preformed anti-HLA
alloantibodies in serum samples of patients awaiting cardiac
transplantation predicts a high likelihood of repeated posi-
tive donor-specific T-cell crossmatch reactivity, with the
consequence of increased waiting time to transplantation.
The complications of long-term LVAD use, together with
the effects of the underlying cardiac disease state, make
such prolongation of the waiting time to transplantation a
Figure 3. Actuarial (Kaplan-Meier) freedoms from TCAD detected by annual coronary angiography. Symbols
represent actual events, positioned along horizontal axis at time of event and by Kaplan-Meier method along
vertical axis. Squares, Nonbridged recipients; triangles, LVAD-bridged recipients.
TABLE 8A. Influence of LVAD bridging on TCAD after heart
transplantation
Positive
first annual
angiogram
RR
95%
Confidence
interval P valueNo. %
LVAD 28/87 31 1.355 0.828-2.217 .27
Control 89/351 26 1 — —
TABLE 8B. Influence of LVAD bridging on TCAD after heart
transplantation
Positive
first annual
angiogram
RR
95%
Confidence
interval P valueNo. %
Status 1* 22/75 29 0.983 0.289-3.338 .977
Status 2* 64/180 34 1 — —
LVAD not sensitized 9/27 30 0.846 0.260-2.751 .781
LVAD sensitized
and treated
5/20 25 0.962 0.241-3.850 .967
LVAD sensitized 14/39 36 1.199 0.338-4.251 .977
*Patients enrolled on United Network for Organ Sharing waiting list be-
tween January 1992 and January 1999 only.
John et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 3 587
A
CD
significant risk factor for morbidity and mortality among
patients on cardiac transplant waiting lists.
Only approximately 35% of patients in the United States
awaiting cardiac transplantation receive transplants during a
given year, whereas nearly 30% die awaiting a suitable
donor. The likelihood of transplantation is even lower for
highly sensitized patients with high levels of circulating
anti-HLA antibodies. Much of the data on sensitized pa-
tients has emerged from extensive experience with renal
transplant recipients. Potential primary or reoperative renal
transplant candidates with high levels of these antibodies
are subject to prolonged waiting periods for a transplant. On
the basis of the experience in renal transplantation, potential
cardiac allograft recipients with PRA levels greater than
20% require a negative prospective (before transplantation)
donor-specific lymphocytotoxic crossmatch to receive the
organ. Thus individuals whose serum samples repeatedly
yield positive crossmatch reactions have longer waiting
times until a crossmatch-negative donor can be found. Al-
though successful heart transplantation in sensitized patients
without a prospective crossmatch has been reported, it has
been our strict policy to perform a prospective donor spe-
cific crossmatch in sensitized patients. This obviously pre-
cludes distant organ procurement for these patients, thereby
narrowing an already shrunken donor pool. Unlike the case
of renal transplant recipients, who can be successfully main-
tained with dialysis for prolonged periods, the lack of a
widely available reliable alternative cardiac support system
(with the exception of LVADs until recently) translates pro-
longation of waiting time into clinical deterioration and some-
times death. As a result, it has been the policy of some
transplant centers to perform only retrospective crossmatches
for cardiac transplant recipients. Our experience demonstrates
that the probability of undergoing transplantation was in-
creased by 4-fold in LVAD recipients who do not acquire IgG
anti-HLA class I antibodies relative to LVAD recipients with
IgG anti-HLA class I antibodies. The development of anti-
HLA class II antibodies also had an impact, although less
significant than that of class I antibodies, on waiting times to
transplantation in LVAD recipients.
We have shown that the presence of anti-IgG class II
antigens at the time of cardiac transplantation was highly
predictive of early high-grade cellular rejection as well as of
higher cumulative annual rejection frequency in the post-
transplantation period.13 Acute cellular rejection of cardiac
allografts is accompanied both in the circulation and in the
allograft of recipient T cells that react with donor HLA-DR
peptides presented by self–antigen-presenting cells.27 The
relationship between recurrent high-grade cellular rejections
and preexisting IgG anti-class II antibodies may be related
to the presence of circulating presensitized memory B cells
in allosensitized patients that are capable of reacting with
HLA-DR molecules and presenting cryptic epitopes to
helper CD4 T cells.28,29 More importantly, we have shown
that immunomodulatory therapy reduced the prolonged
waiting time as well as the increased risk for acute rejection
in highly sensitized patients.
Immunologic treatment of sensitized LVAD recipients
before transplantation with intravenously administered cy-
clophosphamide together with IVIg significantly reduced
serum alloreactivity,30 also reducing waiting list times to
those of nonsensitized patients. The mechanism by which
IVIg transiently reduces anti-HLA serum reactivity is not
well defined but may be related to the presence in the IVIg
preparation of soluble HLA class I molecules that bind
circulating anti-HLA antibodies31,32 or of non–comple-
ment-fixing antibodies against HLA class I molecules that
compete with recipient alloreactive antibodies by binding to
nonpolymorphic determinants in the -helical region of
HLA class I molecules.33 Although IVIg stimulates the
production of immunoglobulin M anti-idiotypic blocking
antibodies to HLA in recipient serum,34 this immunomodu-
latory mechanism is unlikely to account for the rapid, tran-
sient, and nonsustained clinical effect observed with IVIg
administration. IVIg therapy has been used with consider-
able success in the treatment of highly sensitized patients
awaiting kidney transplantation.35 Glotz and associates36
reported on the use of high-dose IVIg therapy in highly
sensitized patients receiving dialysis treatment to allow
decrease in HLA-specific alloantibodies. Cyclophospha-
mide administered long term in low doses has been used
with increasing success in the treatment of several autoim-
mune diseases that are characterized by hyperactivity of the
immune system.37 Because the mode of action of cyclo-
phosphamide involves antimitotic mechanisms, it is most
effective when used against B cells that are rapidly prolif-
erating. Although immunoglobulin production may be aug-
mented shortly after initiation of cyclophosphamide ther-
apy, B-cell function is suppressed by long-term low-dose
therapy. Cyclophosphamide therapy has also been shown to
have a selective suppressive effect on discrete stages of the
B-cell cycle, including both proliferation and differentia-
tion.38
Rose and coworkers39 reported an association between
anti-HLA antibodies and accelerated coronary artery dis-
ease in cardiac allograft recipients. In a large retrospective
study of 463 cardiac allograft recipients, Lavee and cowork-
ers7 showed that the degree of PRA elevation correlated not
only with the occurrence of early acute rejection but also
with subsequent development of graft atherosclerosis. Thus
these studies suggested an association between the presence
of anti-HLA antibody and accelerated graft atherosclerosis.
However, direct histopathologic examination of the cardiac
allograft has not demonstrated a primary role for alloanti-
body in graft disease.40 The definitive role of cell-mediated
immune responses probably leaves a complementary role
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for alloantibody in graft atherosclerosis, possibly by en-
hancing T-cell binding to the vascular endothelium. We did
not find an association between the presence of preformed
anti-HLA antibodies and the development of TCAD. It is
possible that the current immunosuppressive regimens, the
improved detection and treatment of acute rejection, and
prophylaxis for cytomegalovirus infections have reduced
the impact of preformed antibodies on TCAD development.
In conclusion, because the frequency of HLA sensitiza-
tion has shown to be increased among LVAD recipients it is
especially important that PRA testing be performed at reg-
ular intervals for LVAD recipients awaiting cardiac trans-
plantation. Before transplantation all patients with elevated
PRA levels (20%) should undergo prospective lympho-
cytotoxic crossmatching with donor T- and B-lymphocytes
with determination of IgG and immunoglobulin M specific-
ities. Because of the current time constraints on cold isch-
emic time of heart preservation, it is not feasible to perform
prospective crossmatching for every cardiac transplant re-
cipient. A positive IgG lymphocytotoxic crossmatch against
donor T lymphocytes should be a definite contraindication
for heart transplantation. It has been suggested that patients
who are highly sensitized before transplantation may be at
risk for the development of anti-HLA antibodies in the
posttransplantation period, thereby potentially contributing
to deleterious effects on the cardiac allograft. Thus these
patients merit close follow up and possibly even more
intense and targeted immunosuppression. Further studies
are required to assess the role of more selective and less
global immunosuppression in this group of sensitized pa-
tients. With increasing use of LVADs for patients with heart
failure, a better understanding of their immunologic inter-
actions and their subsequent clinical consequences is essen-
tial to achieve continued successful outcomes fir patients
with end-stage heart failure.41,42
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Discussion
Dr Anees J. Razzouk (Loma Linda, Calif). The limited supply
of donor organs has caused an increase in the use of mechanical
circulatory support to bridge potential recipients to cardiac trans-
plantation. Allosensitization to HLA class I or II antigens, defined
as PRA greater than 10%, can develop during LVAD support and
has become a clinical problem of significance. Concerns regarding
the adverse effects of sensitization on graft rejection and recipient
survival have prompted different therapies to reduce PRA before
transplantation. Such regimens have included plasmapheresis,
avoidance of cellular blood product transfusions in LVAD recip-
ients, administration of IVIg, and immunosuppression. There is
significant controversy with regard to the management of sensi-
tized patients awaiting transplantation. Strict protocols requiring a
negative prospective crossmatch before transplantation result in a
decreased donor pool and a longer duration of support in sensitized
LVAD recipients. Such patients are often denied an otherwise
suitable donor because of a positive crossmatch. This policy can
translate into a longer duration of mechanical support, with in-
creased inherent morbidity such as stroke and infection.
John and colleagues from Columbia are to be commended for
this significant contribution and their creative management of this
difficult group of patients awaiting cardiac transplantation. Their
large retrospective series of 520 adult cardiac allograft recipients
included 105 patients who were supported with LVADs. Sixty-
eight of the 105 LVAD recipients, that is 65%, acquired sensiti-
zation at the time of transplantation. Twenty-six sensitized LVAD
recipients were treated with IVIg and cyclophosphamide before
transplantation. The major findings of their study were as follows:
(1) Sensitized LVAD recipients had an increased risk of acute
rejection during the first year, and this was reduced by pretrans-
plantation immunomodulation therapy. (2) There was no signifi-
cant difference in posttransplantation survival or graft vasculopa-
thy between LVAD and nonbridged recipients, regardless of the
PRA level or the use of immunomodulation therapy. (3) Sensitized
untreated LVAD recipients were less likely to receive transplants
within 2 months than were nonsensitized LVAD recipients. This
brings me to my first question. How much did your policy to
perform a prospective crossmatch contribute to the prolonged
waiting time of the sensitized untreated LVAD patients? Another
way of asking is, would you consider intraoperative or perioper-
ative plasmapheresis followed by IVIg to allow cardiac transplan-
tation in sensitized patients without a prospective crossmatch?
Dr John. Actually, since the conclusion of the study we have
performed cardiac transplantation in about 6 or 7 patients despite
a positive crossmatch. All these patients had waited for prolonged
periods because of repeated positive crossmatches, and their con-
ditions were deteriorating while they were on the waiting list. As
a result, we performed a retrospective crossmatch and went ahead
with the transplant, treating the patients with plasmapheresis and,
more importantly, perioperative IVIg with cyclophosphamide
starting before transplantation. Six of these 7 patients survived,
although 1 had repeated humoral rejections after transplantation,
which we believe is important and is why we believe that doing
prospective crossmatching is important.
Dr Razzouk. You report the highest incidence of allosensiti-
zation associated with LVAD support in the literature, 65%. How
often do you check the PRA, and have you noticed a decrease in
the PRA with time? In other words, is this a transient sensitization?
Dr John. I think that several other groups have documented
LVAD sensitization in the range of 40% to 60%, and certainly we
test PRA levels at monthly intervals in these patients. PRA levels
are known to change with time. Thus it is our practice to check
PRA levels at monthly intervals.
Dr Razzouk. My last question relates to the incidence of
high-grade acute rejection among the sensitized patients during the
first year after transplantation. Were those mostly humoral or
cellular rejection episodes? And did the beneficial effect of IVIg
and cyclophosphamide against rejection extend beyond the first
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year after transplantation? Should this group of sensitized patients
receive more intense long-term immunosuppression and more rig-
orous surveillance after transplantation?
Dr John. The incidence of rejection refers to cellular rejection.
The incidence of humoral rejection in this entire cohort of patients
was remarkably low. Certainly, sensitized treated patients do re-
ceive more monitoring because of the implementation of the new
protocol, close watch of their immunosuppression, and we believe
that this contributes to the trend that we observed toward increased
survival in the sensitized treated group of patients. Certainly the
effect of IVIg and cyclophosphamide does not persist beyond the
first year after transplantation, but I think that these patients go into
the transplantation without these deleterious antibodies, and that
gives them the maximum benefit.
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